NRW.Bank

GEMESYS, a German tech company, specializes in developing advanced AI chips. Founded as a spin-off from Ruhr-University Bochum, the company leverages memristors, novel electronic components, to create highly efficient neural network processing systems. Their technology enables on-device AI training and inference, opening up new possibilities for Edge AI applications.

Valuedesk provides a company-wide solution for recording, analyzing, and implementing improvements and savings. Its platform enables transparency and communication for teamwork and is complemented by workshops, targeted methodological training, and seminars. The solution is used across industries such as automotive suppliers, biotechnology, energy and environment, food, furniture, construction, chemicals and raw materials, information technology, transport and logistics, telecommunications, electronics, pharmaceuticals and cosmetics, machine and plant construction, and textiles. Founded in 2017 and based in Bielefeld, Germany, Valuedesk specializes in structured savings and operations efficiency management, applying systematic approaches to identify improvement opportunities, develop implementation concepts, and support clients with consulting and process management software to achieve long-term profitability.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Black Semiconductor is a technology company focused on graphene integrated photonics. It develops photonic circuits directly fabricated on silicon-scale electronics, enabling chip-to-chip communication at higher data transfer rates, over longer distances, with reduced energy consumption. By combining electronics and photonics on a single wafer, the company aims to overcome bandwidth and energy limits of traditional copper interconnects. The approach uses graphene to connect electrical signals and light, offering CMOS-compatible processing that fits into existing chip production pipelines. This enables faster, more energy-efficient data transfer and scalable integration for data centers and other computing applications. The company is advancing a scalable 300mm wafer pilot line and has established fabrication facilities in Aachen, Germany (FabOne) to support scalable production.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.

ichó systems gmbh is a company based in Duisburg, Germany, specializing in the development of interactive systems aimed at promoting and activating individuals with cognitive impairments, particularly those suffering from dementia, stroke, or Parkinson's disease. Its flagship product, the ichó therapy ball, utilizes advanced sensor technology to respond to various interactions such as rolling, catching, or shaking, with visual and auditory stimuli like colored lights, vibrations, sounds, and music. The therapy ball is equipped with multiple applications designed to enhance motor and cognitive skills, developed in collaboration with healthcare professionals. Since its market introduction in 2020, ichó has been implemented in over 850 care facilities, receiving endorsements from medical professionals for its effectiveness. In 2023, the therapy program was recognized and funded by care insurance as a preventive service. ichó aims to facilitate outpatient care, allowing patients to engage in therapeutic activities comfortably at home.

Einhundert Energy is a company based in Cologne, Germany, specializing in smart services for green and digital energy supply. Established in 2017, it focuses on providing comprehensive solutions for tenant electricity, which includes planning, installation, operation, and maintenance of photovoltaic systems. The company enables tenants and entrepreneurs to access low-cost solar energy while ensuring transparency in their energy billing through a dedicated app. This app allows users to monitor their power consumption effectively, promoting cost control and efficiency. Einhundert Energy's digital billing solution integrates various technologies, including heat and water billing, smoke detectors, heat pumps, and e-charging stations, catering to the diverse needs of property managers and tenants alike.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Aifora GmbH is a technology company based in Düsseldorf, Germany, specializing in retail automation through its advanced optimization software. Founded in 2017, Aifora's platform leverages big data and machine learning to help retail businesses understand and predict consumer behavior effectively. It offers solutions for price optimization and stock management, assisting clients in determining optimal order quantities and improving merchandise flow. By creating a shared data ecosystem, Aifora enables brands and retailers to make informed decisions that enhance consumer experiences and drive profitability. The company's use of deep learning algorithms allows for more accurate pricing and promotional strategies, while intelligent automation streamlines repetitive tasks, allowing merchandisers to concentrate on product innovation and enhancing customer engagement.

Founded in 2015, Semalytix develops an AI-driven platform that extracts and summarizes trends in value perception of high-cost therapies across areas such as oncology, immunology, and metabolism. The platform gathers evidence from diverse data sources like CRM systems, social media, clinical studies, and external providers.

ichó systems gmbh is a company based in Duisburg, Germany, specializing in the development of interactive systems aimed at promoting and activating individuals with cognitive impairments, particularly those suffering from dementia, stroke, or Parkinson's disease. Its flagship product, the ichó therapy ball, utilizes advanced sensor technology to respond to various interactions such as rolling, catching, or shaking, with visual and auditory stimuli like colored lights, vibrations, sounds, and music. The therapy ball is equipped with multiple applications designed to enhance motor and cognitive skills, developed in collaboration with healthcare professionals. Since its market introduction in 2020, ichó has been implemented in over 850 care facilities, receiving endorsements from medical professionals for its effectiveness. In 2023, the therapy program was recognized and funded by care insurance as a preventive service. ichó aims to facilitate outpatient care, allowing patients to engage in therapeutic activities comfortably at home.

COMPEON is a prominent financing portal in Germany that specializes in providing tailored financial solutions for small and medium-sized enterprises (SMEs). Established in 2013, the platform enables businesses to submit financing queries at no cost, receiving customized offers from a network of over 220 banks, leasing companies, and alternative financing providers. Each year, COMPEON manages financing inquiries amounting to €2.5 billion, facilitating access to various financial products including credit, loans, leasing agreements, factoring, and alternative financing options such as mezzanine capital and project financing. The firm is led by its founders and managing directors, Kai Böringschulte, Dr. Nico Peters, and Dr. Frank Wüller, and is supported by notable investors including DvH Ventures, b-to-v, and Tengelmann Ventures.

Ubirch develops an Internet of Things software security system using blockchain technology. It provides software for secure data transmission from IoT sensors, serving industries such as production, insurance, energy, supply chain, and logistics. Additionally, Ubirch offers a platform for publishing and sharing carbon footprint data, enabling companies to calculate their Scope 3 emissions and publish them in an auditable manner.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

Taxy.io develops a software platform that automates tax consulting and research using artificial intelligence. It serves tax professionals, lawyers, auditors, and corporate finance departments by providing a central hub for digital tax intelligence through semantic search and automated legal analysis.

Einhundert Energy is a company based in Cologne, Germany, specializing in smart services for green and digital energy supply. Established in 2017, it focuses on providing comprehensive solutions for tenant electricity, which includes planning, installation, operation, and maintenance of photovoltaic systems. The company enables tenants and entrepreneurs to access low-cost solar energy while ensuring transparency in their energy billing through a dedicated app. This app allows users to monitor their power consumption effectively, promoting cost control and efficiency. Einhundert Energy's digital billing solution integrates various technologies, including heat and water billing, smoke detectors, heat pumps, and e-charging stations, catering to the diverse needs of property managers and tenants alike.

Unu GmbH, founded in 2013 and headquartered in Berlin, Germany, specializes in the design, development, and sale of electric scooters. The company aims to enhance urban mobility by providing stylish, emission-free, and quiet scooters that feature portable batteries, allowing users to charge them conveniently at home. Unu's first electric scooter was launched in 2014, marking the beginning of its commitment to connecting people with their cities. In addition to selling scooters through retail outlets and online, the company offers various financing options and after-sales support services to enhance customer experience.

ichó systems gmbh is a company based in Duisburg, Germany, specializing in the development of interactive systems aimed at promoting and activating individuals with cognitive impairments, particularly those suffering from dementia, stroke, or Parkinson's disease. Its flagship product, the ichó therapy ball, utilizes advanced sensor technology to respond to various interactions such as rolling, catching, or shaking, with visual and auditory stimuli like colored lights, vibrations, sounds, and music. The therapy ball is equipped with multiple applications designed to enhance motor and cognitive skills, developed in collaboration with healthcare professionals. Since its market introduction in 2020, ichó has been implemented in over 850 care facilities, receiving endorsements from medical professionals for its effectiveness. In 2023, the therapy program was recognized and funded by care insurance as a preventive service. ichó aims to facilitate outpatient care, allowing patients to engage in therapeutic activities comfortably at home.

Holocafé ist a franchiser company developing exclusive, shared-space VR experiences for location-based entertainment. Content aside, we have developed an entire one-stop platform solution to provide leisure operators with all tools they need: From ticketing and online payment over staff scheduling and accounting to store automization and content distribution. We are presently running three pilot stores in Germany with a fourth one scheduled to open this spring, in addition to a number of international licensees.

Hemovent is a medical technology company based in Aachen, Germany, focused on developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Founded by Christof Lenz and Oliver Marseille, the company aims to create an innovative device that supports or replaces heart and lung functions during cardiac or respiratory failure. Hemovent's device is designed to provide respiratory support for patients with severely damaged lungs and serves as a temporary life support system, taking over heart function in cases of acute heart failure. This technology enables hospitals to stabilize patients and address underlying health issues effectively, while also allowing for increased patient mobility during treatment.

Unu GmbH, founded in 2013 and headquartered in Berlin, Germany, specializes in the design, development, and sale of electric scooters. The company aims to enhance urban mobility by providing stylish, emission-free, and quiet scooters that feature portable batteries, allowing users to charge them conveniently at home. Unu's first electric scooter was launched in 2014, marking the beginning of its commitment to connecting people with their cities. In addition to selling scooters through retail outlets and online, the company offers various financing options and after-sales support services to enhance customer experience.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Hemovent is a medical technology company based in Aachen, Germany, focused on developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Founded by Christof Lenz and Oliver Marseille, the company aims to create an innovative device that supports or replaces heart and lung functions during cardiac or respiratory failure. Hemovent's device is designed to provide respiratory support for patients with severely damaged lungs and serves as a temporary life support system, taking over heart function in cases of acute heart failure. This technology enables hospitals to stabilize patients and address underlying health issues effectively, while also allowing for increased patient mobility during treatment.

Bomedus is a Germany-based medical device company founded in 2011, focused on improving mobility for individuals suffering from chronic back pain. The company develops innovative devices that utilize an electro-therapeutic method to provide permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus aims to enhance the quality of life for patients dealing with pain-related challenges.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Vimecon GmbH, founded in 2005 and headquartered in Herzogenrath, Germany, specializes in the development and production of laser catheters aimed at treating heart diseases, particularly atrial fibrillation. The company also manufactures a range of products for the medical technology and biotechnology sectors, including microscopically small catheters and micro materials handling techniques that facilitate precise measurement and dosage. In addition to its product offerings, Vimecon provides advisory services to various clients in both academic and industrial research and development. Through its innovative solutions, the company aims to enhance healthcare outcomes in the treatment of cardiovascular diseases and cardiac arrhythmias.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.

Founded in 2009, GreenPocket is a leading European specialist in energy management software. It provides innovative solutions for utilities and corporate customers worldwide, leveraging AI, machine learning, and data science to derive value from smart meter data. The company's intuitive platforms enable residential customers and businesses to monitor and reduce their energy consumption, contributing to the digitalization of the energy industry and a sustainable future.

Azeti GmbH, based in Berlin, Germany, is a provider of Internet of Things (IoT) solutions that focus on monitoring and managing technology infrastructures. Founded in 2006, the company offers a range of products, including SONARPLEX, which delivers real-time information for logistics companies, allowing for the monitoring of fuel consumption, vehicle condition, and driver activity. Their SonarWise product connects remote cell sites to a company’s network operations center, enabling real-time oversight of technical equipment and energy usage. Additionally, Azeti provides applications such as SONARMANAGER for centralized management and the azeti Lab app for mobile access. Their solutions cater to various sectors, including telecommunications, data centers, and transportation, facilitating applications like condition monitoring and predictive maintenance. With a focus on customer needs and agile project execution, Azeti serves partners, distributors, and system integrators globally. As of July 2020, Azeti operates as a subsidiary of Aurubis AG, enhancing its capabilities in delivering IoT solutions.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Vimecon GmbH, founded in 2005 and headquartered in Herzogenrath, Germany, specializes in the development and production of laser catheters aimed at treating heart diseases, particularly atrial fibrillation. The company also manufactures a range of products for the medical technology and biotechnology sectors, including microscopically small catheters and micro materials handling techniques that facilitate precise measurement and dosage. In addition to its product offerings, Vimecon provides advisory services to various clients in both academic and industrial research and development. Through its innovative solutions, the company aims to enhance healthcare outcomes in the treatment of cardiovascular diseases and cardiac arrhythmias.

simfy GmbH operates as an online music platform. The company allows to share and store music online, as well as to listen instantly to specific tracks or albums via true on demand streaming. simfy GmbH was founded in 2006 and is based in Cologne, Germany.

Fashionette AG operates a data‑driven online retail platform that connects European consumers with a wide range of designer fashion accessories, including handbags, shoes, sunglasses, watches, jewelry, and pre‑loved pieces. Founded in 2008, the company is headquartered in Düsseldorf and offers a personalized shopping experience through its extensive selection of products.

simfy GmbH operates as an online music platform. The company allows to share and store music online, as well as to listen instantly to specific tracks or albums via true on demand streaming. simfy GmbH was founded in 2006 and is based in Cologne, Germany.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

CEVEC Pharmaceuticals GmbH is a biopharmaceutical company based in Cologne, Germany, specializing in the production of therapeutic proteins and monoclonal antibodies using a unique human cell-based expression system. Founded in 2001, CEVEC has developed the CAP-GO platform, which allows for the efficient production of complex, glycosylated proteins that are challenging to express using conventional cell lines. This platform includes optimized expression vectors, serum- and animal component-free cell line generation, and stable pool generation for recombinant proteins. Additionally, CEVEC offers the CAP-GT platform, facilitating large-scale production of gene therapy vectors, including Lentiviral, Adenoviral, and AAV types. The company also provides contract manufacturing services and has established a strategic collaboration with BioLamina AB, enhancing its capabilities in the biopharmaceutical sector.

Innolume GmbH is a manufacturer of advanced laser diodes based in Dortmund, Germany. Established in 2002, the company specializes in a wide array of optoelectronic devices, including single-mode and broad-area laser diodes, comb-lasers, and semiconductor optical amplifiers. Innolume's products are designed for various applications, such as Raman amplification, optical interconnects, and medical and industrial uses. Notably, the company has developed a novel comb laser light engine that facilitates economical wavelength-division multiplexing for short-reach optical connections in computing environments. This innovation enhances efficiency by reducing the need for multiple lasers and underutilized fiber, significantly lowering costs and power consumption. Innolume has also received recognition for its temperature-independent distributed feedback laser, which has the potential to impact the future of data communication.

Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.

SCIENION AG is a life science company based in Berlin, Germany, specializing in the development and manufacture of ultra-low volume precision dispensing and microarray technologies for the life science and diagnostic industries. The company offers an array of products, including the sciFLEXARRAYER line of liquid handling systems for various sample types, the cellenONE X1 for single cell isolation, and the sciREADER devices for multiplex sample analysis. Additionally, SCIENION provides sciCONSUMABLES to enhance assay performance and offers customized solutions and services for assay development and manufacturing. Its technologies facilitate multiplexed array-based assays, biosensors, and high throughput screening, catering to customers in pharmaceutical, biotech, diagnostic, and academic sectors. Established in 2000, SCIENION operates through distributors in several countries, including Italy, South Korea, and Japan. It became a subsidiary of Cellink AB in 2020.

Innolume GmbH is a manufacturer of advanced laser diodes based in Dortmund, Germany. Established in 2002, the company specializes in a wide array of optoelectronic devices, including single-mode and broad-area laser diodes, comb-lasers, and semiconductor optical amplifiers. Innolume's products are designed for various applications, such as Raman amplification, optical interconnects, and medical and industrial uses. Notably, the company has developed a novel comb laser light engine that facilitates economical wavelength-division multiplexing for short-reach optical connections in computing environments. This innovation enhances efficiency by reducing the need for multiple lasers and underutilized fiber, significantly lowering costs and power consumption. Innolume has also received recognition for its temperature-independent distributed feedback laser, which has the potential to impact the future of data communication.